Off-Label Use
Also known as: Off-label prescribing, Unapproved use, Non-indicated use, Unlabeled use
Off-Label Use refers to the legally permitted practice of prescribing an FDA-approved medication for a condition, patient population, dosage, or route of administration not specified in the official drug labeling. Off-label prescribing is common in medicine and often supported by clinical evidence, though it hasn't undergone formal FDA review for that specific use.
Last updated: February 1, 2026
What Makes a Use “Off-Label”
Categories of Off-Label Use
| Category | Approved | Off-Label Example |
|---|---|---|
| Indication | Type 2 diabetes | Weight loss (before obesity approval) |
| Age group | Adults 18+ | Adolescents 12-17 |
| Dosage | 2.4 mg weekly | 1.0 mg weekly for weight loss |
| Route | Subcutaneous injection | Oral administration |
| Duration | As prescribed | Extended beyond studied period |
| Combination | Monotherapy | Combined with other agents |
On-Label vs Off-Label Comparison
| Aspect | On-Label | Off-Label |
|---|---|---|
| FDA reviewed for use | Yes | No |
| Legal to prescribe | Yes | Yes |
| Evidence required | Phase 3 trials | Varies widely |
| Insurance coverage | Usually covered | May be denied |
| Liability | Standard | Potentially higher |
Legal Framework
What Is Legal
- Physicians prescribing off-label based on clinical judgment
- Pharmacies dispensing valid off-label prescriptions
- Patients using medications as prescribed by their doctor
- Physicians discussing off-label uses with patients
What Is Restricted
- Pharmaceutical companies promoting off-label uses
- Marketing materials for unapproved indications
- Sales representatives discussing non-approved uses (with limited exceptions)
- Misleading claims about off-label effectiveness
Off-Label Use in Peptide Therapy
Historical Examples
| Peptide | Off-Label Period | Now Approved For |
|---|---|---|
| Semaglutide | 2017-2021 (weight loss) | Obesity (Wegovy, 2021) |
| Tirzepatide | 2022-2023 (weight loss) | Obesity (Zepbound, 2023) |
| Liraglutide | 2010-2014 (weight loss) | Obesity (Saxenda, 2014) |
Current Common Off-Label Uses
GLP-1 Agonists:
- Lower-than-approved doses for weight management
- Combined GLP-1 protocols (not studied together)
- Use in patients outside approved BMI criteria
Growth Hormone Secretagogues:
- Anti-aging applications (not FDA approved)
- Athletic performance (prohibited in sport)
- Sleep improvement
Evidence Standards for Off-Label Use
Hierarchy of Evidence
| Level | Evidence Type | Strength |
|---|---|---|
| 1 | Randomized controlled trials | Strongest |
| 2 | Prospective cohort studies | Strong |
| 3 | Retrospective studies | Moderate |
| 4 | Case series/reports | Limited |
| 5 | Expert opinion | Weakest |
What Good Off-Label Prescribing Looks Like
- Based on peer-reviewed research
- Aligned with clinical guidelines or expert consensus
- Patient fully informed of off-label status
- Documented medical reasoning
- Appropriate monitoring for the specific use
Insurance and Off-Label Use
Coverage Factors
| Factor | Impact on Coverage |
|---|---|
| Compendia listing | Often covered if listed |
| Clinical guidelines | May support approval |
| Prior authorization | Usually required |
| Appeal process | Available for denials |
Drug Compendia
Recognized references listing accepted off-label uses:
- DRUGDEX (Micromedex)
- AHFS Drug Information (ASHP)
- Clinical Pharmacology
- National Comprehensive Cancer Network (oncology)
Insurance often covers off-label uses listed in these references.
Risks and Considerations
Potential Concerns
| Risk | Explanation |
|---|---|
| Unknown efficacy | May not work for off-label indication |
| Unknown safety | Different risks in different populations |
| Dosing uncertainty | Optimal dose may differ from approved use |
| Insurance denial | May need to pay out of pocket |
| Liability | Malpractice considerations for prescribers |
Mitigating Factors
- Extensive clinical experience with the use
- Published research supporting the application
- Professional society endorsement
- Informed patient consent
- Appropriate monitoring
Frequently Asked Questions
Is my doctor allowed to prescribe off-label?
Yes. Once FDA approves a drug, licensed physicians can legally prescribe it for any purpose they believe benefits the patient. This is fundamental to medical practice and allows physicians to use their clinical judgment.
How do I know if my prescription is off-label?
Ask your prescriber directly. Off-label status should be discussed during informed consent, including why your doctor believes the use is appropriate, what evidence supports it, and any additional considerations.
Should I be concerned about off-label prescriptions?
It depends on the specific situation. Some off-label uses have decades of clinical experience and strong evidence; others are more experimental. Key questions: What’s the evidence? What are the alternatives? What monitoring will occur? Discuss these with your prescriber.
Does off-label mean experimental?
Not necessarily. Some off-label uses are better established than certain approved uses. “Off-label” simply means FDA hasn’t formally reviewed that specific application. The strength of supporting evidence varies enormously.
Related Peptides
Related Terms
Disclaimer: This glossary entry is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for medical questions.